Therefore, this study demonstrated that CAR-T product with a fixed ratio of 1:1 of CD4+/CD8+ expressing cells is well tolerated and shows potential in treating relapsing/remitting B-ALL [87]. The gene discussed is CD4; the disease is acute lymphoblastic leukemia.